Sigyn Therapeutics, Inc. (OTCMarkets: SIGY)

[ad_1]

About: Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

Interview with Jim Joyce Co-founder, Chairman and CEO

CEO Jim Joyce discusses Sigyn’s recent news over the last couple months which includes a pilot study to address inflammatory CytoVesicles. In the in vitro pilot study, 104nm liposomes were utilized as a model system to assess the ability of Sigyn Therapy’s adsorbent components to deplete CytoVesicles from human blood plasma.  After a two-hour interaction with Sigyn’s adsorbent components, liposome concentrations in human blood plasma were reduced ~90%.  Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

INTERVIEW TRANSCRIPTS:

Coming Soon


The Wall Street Analyzer’s staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.



[ad_2]
Written by The Wall Street Analyzer.
View the original article at here.
The Wall Street Analyzer
wallstreetanalyzer.com

Recommended